News Brief Archive
Asked HHS Secretary Azar to consider policies that increase access to anti-cancer treatments while implementing the President's executive order on Improving Rural Health and Telehealth Access.
Urged Medicare to allow use of non-invasive colorectal cancer screening options in light of COVID; and, if a follow-up colonoscopy is needed, that it is covered with no cost-sharing for the patient.
Teamed up with 100+ patient and health care orgs to oppose a proposed Medicaid Rule that erodes prescription copay coupon assistance programs.
Called on Congress to delay implementation of a new policy that would allow health insurers to exclude cost-sharing assistance from counting towards patients' out-of-pocket maximums.
Provided feedback on the “Preparing for the Next Pandemic” white paper asking that it address high out-of-pocket costs for oral anticancer drugs in future pandemic relief efforts.
Joined the Partnership to Improve Patient Care in a letter to the new VP for Patient Engagement at the Institute for Clinical and Economic Review (ICER), offering to partner in advancing patient engagement and patient-centeredness at ICER.
Expressed support for increased diversity in clinical trials, signing onto an effort urging congressional leadership to include text from HR 913, the CLINICAL TREATMENT Act, in the next COVID-19 relief bill.
Collaborated with the All Cancers Congress in asking U.S. governors to require that all health insurers allow for up to 90-day medication supplies during the COVID crisis.
Engaged in requests for additional funding in the Paycheck Protection Program Health Care Enhancement Act (H.R. 266), a COVID-19 supplemental appropriations bill, to help sustain biomedical research.
Teamed up with 50 cancer groups in urging Congress and HHS to take additional steps to make accessing care easier for cancer patients/survivors during the COVID-19 crisis.
FORCE and 100+ orgs advocated that legislators increase funding for the FY21 Defense Appropriations Act to foster improved research under the DoD CDMRP.
Participated in the Coalition to Improve Access to Cancer Care (CIACC) letter to U.S. House leadership re: including the Cancer Drug Parity Act (H.R. 1730) in the 4th COVID-19 stimulus bill.
We sent a letter to Senate leadership asking for reauthorization of the Protecting Access to Lifesaving Screening (PALS) Act, ensuring access to mammograms for women 40 and older at no cost.
We joined other coalition members in a letter to House leadership urging reauthorization of the PALS and EARLY Acts to ensure continued access to breast cancer education, awareness and screening.
A FORCE staff member made comments at the FDA ODAC hearing in favor of olaparib as maintenance therapy for BRCA+ metastatic pancreatic cancer patients.
FORCE and 100+ orgs advocated that legislators complete FY20 Defense Appropriations Act negotiations and quickly pass/enact the bill to ensure continued funding of the DoD CDMRP.
We wrote South Carolina Senate medical affairs committee members asking that they support genetic counselor licensure in the state.
We joined the MedEx Coalition in asking elected officials to co-sponsor the Medical Expense Savings Act, legislation making the 7.5% threshold for medical expense deductions permanent.
FORCE, along with hundreds of medical and patient advocacy orgs, expressed support for a long-term reauthorization of PCORI.
We authored comments on the FDA's draft industry guidance on developing drugs for the treatment of male breast cancer.
FORCE and two dozen groups urged CMS to reconsider the 14-day Rule, which has created delays in patients receiving test results.
Signed onto a letter urging the President to waive out-of-pocket costs for seniors on Medicare who have precancerous polyps removed during a screening colonoscopy.
We joined over 50 orgs representing patients, advocates, caregivers, researchers, and physicians to support the appointment of Norman Sharpless as FDA Commissioner.
FORCE is supporting legislation (H.R. 4078) to reauthorize and increase funding for the Breast Cancer Education and Awareness Requires Learning Young Act (EARLY) Act.
We played a lead role in drafting coalition comments on the FDA's proposed mammography guideline updates.
Today, the FDA announced a new pilot program called Project Facilitate to assist oncologists in requesting access to unapproved therapies for cancer patients.
FORCE, with over 300 organizations and institutions, is supporting the Ad Hoc Group’s FY2020 recommendation of at least $41.6 billion in funding for the NIH.
We signed onto a letter to Rep. Debbie Wasserman Schultz thanking her for her leadership on the PALS Act, preserving mammograms for women ages 40-49.
FORCE and a group of 20 stakeholders met with Medicare to urge continued coverage of genetic testing for all cancer survivors who meet guidelines.
The government funding bill President Trump signed into law today contained language directing the FDA to ensure breast density information is included in mammography reports.
FORCE spearheaded a stakeholder letter to HHS and CMS expressing concern about interpretation of a national policy which places significant limits on hereditary cancer genetic testing under Medicare.
FORCE joined 50 other orgs in an advertising campaign to stop the proposed changes to Medicare Part D’s Six Protected Classes.
As a Friends of the Cancer Policy Institute member, FORCE provided comments on the International Pricing Index (IPI) Model for Medicare Part B Drugs